Shares in Valeritas (NSDQ:VLRX) fell today after the medical technology company announced its preliminary financial results for the third quarter of 2018. The Bridgewater, N.J.-based company said it expects to post quarterly revenue of approximately $6.9 million, just ahead of the $6.85 million predicted by analysts. Compared to the same period in 2017, Valeritas’ sales are […]
Valeritas Inc.
Valeritas kicks off device registration process in China
Valeritas (NSDQ:VLRX) said today that it began the process to register its wearable insulin delivery device, V-Go, in China. The company noted that it signed an agreement with an unnamed contract research organization to work directly with the China National Drug Administration, in the hopes of winning regulatory approval for V-Go in China. “The China market […]
Valeritas launches V-Go insulin delivery device in Australia
Valeritas (NSDQ:VLRX) said today that it launched its V-Go wearable insulin delivery device in Australia. The company inked an exclusive distribution agreement in Australia with AMSL Diabetes earlier this year. According to the terms of the deal, Valeritas will be responsible for product development, regulatory approval, quality management and manufacturing. AMSL Diabetes will take over the […]
Valeritas tops sales, earnings estimates in Q2
Valeritas (NSDQ:VLRX) topped sales and earnings expectations on Wall Street this week with its second-quarter financial results. The Bridgewater, N.J.-based company posted a net loss of -$10.9 million on sales of $6.5 million for the three months ended June 30, for sales growth of 36% compared with the same period last year. Earnings per share were […]
Valeritas lands distro deal in Czech Republic, Slovakia
Valeritas (NSDQ:VLRX) said today that it inked an expanded deal with Med Trust, its distribution partner in Austria and Germany, to promote and sell the V-Go wearable insulin delivery device in the Czech Republic and Slovakia. According to the terms of the deal, Valeritas will be responsible for product development, regulatory approval, quality management and manufacturing the device while […]
Valeritas touts use of V-Go device compared to insulin injections
Valeritas (NSDQ:VLRX) touted data today from an analysis showing that insulin-dependent people with Type 2 diabetes benefited from using the company’s wearable V-Go insulin delivery device. The study featured people who previously treated their diabetes using multiple daily injections of insulin. After switching to the V-Go device under the care of advanced practitioners, participants were monitored […]
Valeritas launches V-Go insulin delivery device in New Zealand
Valeritas (NSDQ:VLRX) said today that its V-Go wearable insulin delivery device is now available in New Zealand thanks to an exclusive distribution deal with NZMS Diabetes. According to the terms of the agreement, Valeritas will be responsible for product development, regulatory approval, manufacturing and quality management while NZMS Diabetes will take over the sales, marketing, customer […]
Valeritas touts positive results for V-Go wearable insulin delivery device
Valeritas (NSDQ:VLRX) shares jumped this morning after the company touted positive results from its Enable study, showing that patients who switched from insulin pens and syringes to the company’s wearable V-Go insulin delivery device experienced improved blood glucose levels and lowered their daily insulin dose. The company presented three posters at this year’s meeting of the […]
Valeritas inks distro deal for V-Go device in Austria, Germany
Valeritas (NSDQ:VLRX) said today that it signed an exclusive distribution deal with Med Trust to commercialize its V-Go insulin delivery device in Austria and Germany. According to the terms of the agreement, Valeritas will be responsible for product development, regulatory approval, quality management and manufacturing. Med Trust will take over the sales, marketing and distribution activities […]
Valeritas touts new data for insulin delivery device
Valeritas (NSDQ:VLRX) touted data today from two new studies of its V-Go wearable insulin delivery device in patients with Type II diabetes. In one three-month evaluation of 60 people with Type II diabetes, researchers assessed if using V-Go could improve glycemic control in patients who were uncontrolled on prior treatment regimens. “Poor glycemic control (A1C above […]
